Mitigation of gastrointestinal acute radiation syndrome by promoting clusterin-mediated intestinal regeneration
Active Cooperative Agreement Awarded Last action
- Award ID
- U01AI186969
- Recipient
-
Duke University UEI TP7EK8DZV6N5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,901,786
Award facts
- Assistance listing
- 93.310 Trans-NIH Research Support
- Completion date 38% complete
- Funding agency
- Office of the Director National Institutes of Health, Department of Health and Human Services
- Place of performance
- Durham, NC 27708, USA
Award details come from USAspending.gov.
Description
- Abstract
- The radiation tolerance of the gastrointestinal (GI) tract can be exceeded in radiation accidents or in the case of nuclear warfare, resulting in a lethal GI acute radiation syndrome (GI-ARS). There are no current FDA- approved medical countermeasures to mitigate GI-ARS; thus, there is an urgent need to identify key mechanisms of repair and regeneration in the irradiated intestinal epithelium. We have shown that the regeneration of the intestinal epithelium in response to severe radiation injury is mediated through revival stem cells (revscs), which are generated through fetal-like reprogramming and identified by a marker gene clusterin (CLU) (the mouse ortholog of human CLU). Remarkably, whole animal deletion of CLU significantly sensitizes mice to GI-ARS, while GI-ARS in mice is significantly mitigated via treatment with exogenous mouse CLU protein starting 24 hours post-irradiation. In addition, our preliminary data suggest that the cgas-sting pathway acts as an upstream regulator of CLU in the irradiated intestinal epithelium. Treatment of mice with a sting agonist MSA-2 starting 24 hours after irradiation significantly improves the regeneration of irradiated small intestines. Thus, the overall goal of this proposal is to develop novel mitigators of the GI-ARS that promote the regeneration of irradiated intestinal epithelium by targeting the sting-CLU axis. In aim 1, we will define the mechanisms by which CLU mitigates the development of GI-ARS. In aim 2, we will dissect the sting-CLU axis in regulating the development of GI-ARS. Successful completion of the proposed study will demonstrate the key role of CLU in promoting the regeneration of the intestinal epithelium following acute radiation injury in mice and human intestinal organoids. We anticipate that our findings will significantly impact the successful development of GI-ARS mitigators that target the sting-CLU axis.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $110,922 | |
| Amendment | $380,106 | |
| Amendment | $380,106 | |
| Amendment | $515,326 | |
| Original award | $515,326 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Health Network | $110,922 | |
| University Health Network | $113,400 |
Quick answers
Who received award U01AI186969?
U01AI186969 was awarded to Duke University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 2, 2024.
How much is award U01AI186969 worth?
$1,901,786 has been obligated on U01AI186969.
Which agency awarded U01AI186969?
National Institute of Allergy and Infectious Diseases (National Institutes of Health) awarded U01AI186969, with funding from Office of the Director (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award